1033765-97-7

Upstream product

• 54734-85-9 2-amino-5-nitrobenzenesulfonamide 
• 15862-72-3 ethyl pipecolate 
• 4533-95-3 5-nitro-2-chlorobenzenesulfonyl chloride 
• 32002-38-3 1-amino-piperidine-2-carboxylic acid ethyl ester 
• 96-72-0 2-chloro-5-nitrobenzenesulfonamide 
• 96-73-1 2-chloro-5-nitro-benzenesulfonic acid 
• 1000313-18-7 N-(4-(methanesulfonylamino)-2-sulfamoyl-phenyl)malonamic acid ethyl ester 
• 1000313-20-1 (7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-1λ6-benzo[e][1,2,4]thiadiazin-3-yl)-acetic acid 
• 1033766-15-2 1-(4-fluorobenzylamino)piperidine-2-carboxylic acid ethyl ester 
• 691361-76-9 2-amino-5-(methanesulfonylamino)benzenesulfonamide 
• 459-57-4 4-fluorobenzaldehyde 
• 1033766-16-3 1-{(4-fluorobenzyl)[2-(7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-1;λ6-benzo[1,2,4]thiadiazin-3-yl)acetyl]amino}piperidine-2-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase

Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-one analogs were discovered as a novel class of inhibitors of genotype 1 HCV NS5B polymerase. Among these, compound 4c displayed potent inhibitory activities in biochemical and replicon assays (IC50 (1b) 50 (1b) = 34 nM) as well as good stability towards human liver microsomes (HLM t1/2 = 59 min).

SATURATED FUSED [1,2-B] PYRIDAZINONE COMPOUNDS

The invention is directed to saturated fused [1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.